Lysophosphatidic acid in patients with ovarian cancer

Clinical Ovarian Cancer

Volumn 3, Issue 1, 2010, Pages 41-46

  Sedláková, Iva ^a   Vávrová, Jaroslava ^a   Tošner, Jindřich ^a   Hanousek, Ladislav ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b Hospital Pardubice   (Czech Republic)

Author keywords

Biomarker; Early stage disease; Endometrial ovarian cancer; Phospholipid

Indexed keywords

1 MYRISTOYL 2 HYDROXY SN GLYCEROPHOSPHATIDIC ACID; 1 OLEOYL 2 HYDROXY SN GLYCEROPHOSPHATIDIC ACID; 1 PALMITOYL 2 HYDROXY SN GLYCEROPHOSPHATIDIC ACID; 1 STEAROYL 2 HYDROXY SN GLYCEROPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CAPILLARY ELECTROPHORESIS; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PHOSPHOLIPID BLOOD LEVEL; ULTRAVIOLET RADIATION;

EID: 77953534094     PISSN: 19414390     EISSN: 19414404     Source Type: Journal    
DOI: 10.3816/COC.2010.n.007     Document Type: Article

References (16)

1. Schwartz PE, Taylor KJ. Is early detection of ovarian cancer possible? Ann Med 1995; 27:519-28.
2. Fishman DA, Bozorgi K. The scientific basis of early detection of epithelial ovarian cancer: The National Ovarian Cancer Early Detection Program (NOCEDP). Cancer Treat Res 2002; 107:3-28.
3. So J, Navari J, Wang FO, et al. Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol 2004; 95:314-22.
4. Xiao YJ, Schwartz B, Washington M, et al. Electrospray ionization spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophos-pholipid contents in malignant versus nonmalignant ascitic fluids. Anal Biochem 2001; 290:302-13.
5. Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001; 93:762-8.
6. Lee Z, Swaby FR, Liang Y, et al. Lysophophatidic Acid Is a Major Regulator of Growth-Regulated Oncogene in Ovarian Cancer. Cancer Res 2006; 66:2740-8.
7. Eder AM, Sasagawa T, Mao M, et al. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000; 6:2482-91.
8. Ozols R F, Rubin SC, Thomas G, et al. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Zouny RC, eds. Principles and Practisse of Gynecologic Oncology. Philadelphia: Lippincott-Raven Publishers; 1997:958.
9. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO; 1979.
10. Xu Y, Shen Z, Wiper D W, et al. Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers. JAMA 1998; 280:719-23.
11. Sedláková I, Vávrová J, Tošner J, et al. Lysophosphatidic acid in ovarian cancer patients. Ceska Gynekol 2006; 71:312-7. (Pubitemid 44252138)
12. Baker DL, Morrison P, Miller B, et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 2002; 287:3081-2.
13. So J, Wang F, Navari J, et al. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol 2005; 97:870-8.
14. Sutphen R, Xu Y, Wilbanks D, et al. Lysophospholipids Are Potential Biomarkers of Ovarian Cancer. Cancer Epidem. 2004; 13:1185-91.
15. Okita M, Gaudette DC, Mills GB, et al. Elevated levels and altered fatty acid composition of plasma lysophosphatidylicholine in ovarian cancer patients. Int J Cancer 1997; 71:31-4.
16. Wang P, Wu X, Chen W, et al. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol 2007; 104:714-20.